Clinical Trials

Do you have heart failure and need treatment with intravenous (IV) diuretics? This study is exploring the use of chloride supplementation in people with heart failure who require treatment with IV diuretics, which are used to help rid your body of excess water and salt. To participate in this study, you must have heart failure with signs of volume overload (rales, edema, elevated jugular venous pressure [JVP], or weight gain of at least 5 pounds) requiring treatment with IV diuretics. This study takes place in New Haven, Connecticut.

Do you or your child have severe asthma that is not easily controlled by inhaled corticosteroids? This study evaluates the use of five different asthma medicines to treat adults and adolescents with severe asthma. To participate in this study, you or your child must be 12 years old or older. This study takes place in multiple locations across the United States.

Have you been diagnosed with obstructive sleep apnea (OSA) and been referred to the Yale New Haven Hospital Sleep Center for continuous positive airway pressure (CPAP) treatment? This study is examining how the features that can raise or lower the risk of OSA can impact how well CPAP works in an individual. Researchers will use detailed sleep studies to determine which features contribute to OSA. Results from this study will help researchers develop treatment plans that can lead to personalized OSA treatments to improve patient lives. To participate in this study, you must be at least 19 years old. This study takes place in North Haven, Connecticut.

DIVA is a pragmatic randomized clinical trial (RCT) to determine: among (P) preterm infants born 24-27 6/7 weeks gestation undergoing extubation from mechanical ventilation, whether (I) Non-invasive neurally adjusted ventilatory assist (NIV-NAVA) (C) compared with Non-synchronized nasal intermittent positive pressure ventilation (NS-NIPPV), will reduce the incidence of (O) extubation failure within (T) 5 days (120 hours) of extubation.

The Bashir™ Endovascular Catheter has been designed to administer therapeutic agents in the peripheral vasculature. Because of the unique design of the catheter, with its six expandable infusion limbs, the Bashir™ Endovascular Catheter has the ability to: 1. Create a much larger central channel for blood flow, thereby utilizing the body's own endogenous fibrinolytic agents to lyse the clot, and 2. Greatly enhance the radial dispersion of a catheter-administered thrombolytic agent throughout the thrombus. Expansion of the multiple arms of the basket in the infusion catheter causes fissuring of the clot. The net result is that a greater surface area of clot is exposed to both endogenous and exogenously administered lytic agents, thereby promoting clot dissolution.

The overall objective of research is to test, adapt, refine and validate the HEMOTAG® system to be used outside the usual medical care environments to reduce hospital readmissions.

The objective of the ALA-LHC is to establish a national cohort of young adults for the purpose of defining lung health and developing targets to intercept chronic lung disease at its earliest stages.

Are you an adult female with LAM? If so, you may be able to participate in this clinical study where researchers are observing patients who are taking or have taken a certain kind of medication, mammalian target of rapamycin (mTOR), to treat lymphangioleiomyomatosis, also known as LAM. You must be at least 18 years old to take part. The study is taking place at locations in California, Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota, Missouri, New York, Ohio, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, and Washington.

Does your child have asthma? If so, they may be eligible to participate in a study about whether using a smartphone application can improve asthma management. To participate, your child must be between the age of 12 and 18 and have an iPhone or Android device on which an app can be installed. The study is taking place at the University of South Florida in Tampa, Florida, and participants are expected to remain in the Tampa Bay area for the duration of the study.

Are you an adult with atrial fibrillation? In this study, researchers are comparing a continuous direct oral anticoagulation (DOAC) use versus time-limited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) for persons with atrial fibrillation and a moderate risk of stroke. Participants must be between the ages of 22 and 85 and have a history of atrial fibrillation. The study is taking place at locations in California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Carolina, Texas, Virginia, Wisconsin, and Washington, D.C.